Summary & Overview
CPT 0007U: ToxProtect Urine Drug Screen with DNA Authentication
CPT code 0007U designates a Proprietary Laboratory Analyses (PLA) test for ToxProtect by Genotox Laboratories LTD: a combined presumptive urine drug screen with confirmatory testing for detected drugs plus DNA analysis of a buccal swab to authenticate the urine source. This PLA code is notable because it maps to a single manufacturer's test, which has implications for billing clarity, payer policy, and clinical documentation when source verification is required.
Key payers in the national analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of common payer coverage considerations, typical sites of service for collection and processing, and the clinical context in which source-authenticated toxicology testing is used.
Readers will learn what CPT code 0007U represents, why PLA codes matter for lab billing and prior authorization workflows, and how this combined toxicology-and-DNA test differs from standard drug screens. The report summarizes available benchmarking and policy themes relevant to lab providers and payers, highlights documentation and specimen requirements typically associated with source authentication testing, and identifies where additional payer-specific guidance or prior authorization may be expected. Data not available in the input will be flagged where applicable.
Billing Code Overview
CPT code 0007U is a Proprietary Laboratory Analyses (PLA) code that describes a single, manufacturer-specific laboratory test: ToxProtect by Genotox Laboratories LTD. The test is a presumptive urine drug screen with laboratory confirmation of any drugs identified, combined with a DNA analysis of a buccal (cheek) swab to authenticate the urine sample source.
Service type: Laboratory testing — combined toxicology screening with confirmatory testing and DNA source verification.
Typical site of service: Clinical laboratory or reference laboratory, with specimen collection occurring in outpatient or ambulatory collection settings (urine specimen and buccal swab collection).
Clinical & Coding Specifications
Clinical Context
A 28-year-old patient presents to an outpatient occupational medicine clinic after workplace suspicion of substance use. A urine sample is collected for a presumptive urine drug screen that includes confirmation testing for any identified substances. Because there is concern about specimen tampering or substitution, a buccal swab is collected at the same visit for DNA analysis to authenticate that the urine specimen originated from the patient. The clinic documents informed consent and chain-of-custody as required. The urine screen with reflex confirmation and the buccal swab for source authentication are sent to Genotox Laboratories LTD for processing under the proprietary test name ToxProtect. Typical workflow steps: patient registration and consent, specimen collection (urine and buccal swab), labeling and chain-of-custody documentation, sample shipment to the reference laboratory, laboratory presumptive immunoassay or screening, confirmatory testing (e.g., GC-MS or LC-MS/MS) on positives, DNA STR analysis for buccal swab and comparison to urine-derived DNA, and reporting of combined results to the ordering provider. Typical sites of service include outpatient clinics, occupational health centers, employer-directed testing sites, substance use treatment programs, and forensic collection centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard reporting | Use when no specific modifier applies and full service is billed |
11 | Primary procedure | Use when this service is the primary procedure performed on the same date |
22 | Increased procedural services | Use when documentation shows substantially greater complexity or effort for the laboratory processing beyond typical expectations |
26 | Professional component | Use when reporting only the professional component (interpretation/report) if separated from technical lab component |
52 | Reduced services | Use when testing is partially reduced or limited from the full described service |
53 | Discontinued procedure | Use if testing was begun but discontinued for documented clinical reasons |
56 | Preoperative services | Not commonly used for this assay; use only if testing performed as part of discontinued preoperative evaluation by another provider |
62 | Two surgeons | Rare for lab test; use only when two qualified laboratories or clinical entities share responsibility per payer rules |
78 | Unplanned return to the operating/procedure room | Not typically applicable; include only if a procedural re-collection is required during the same surgical episode |
80 | Assistant surgeon | Not applicable to laboratory testing; report only if a separate professional assistant role is recognized by payer |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207Q00000X | Clinical Pathology | Laboratory directors and clinical pathologists overseeing toxicology and DNA testing |
| 207L00000X | Anatomic and Clinical Pathology | Pathologists involved in test validation and interpretation of confirmatory toxicology |
| 2084P0800X | Occupational Medicine | Clinicians who order workplace-related drug testing and chain-of-custody collections |
| 332B00000X | Forensic Toxicology | Forensic toxicologists and specialized labs performing confirmatory testing and specimen authentication |
| 363A00000X | Medical Laboratory Technician/Technologist | Technologists who perform the assays and DNA authentication workflows |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
Z03.89 | Encounter for observation for other suspected diseases and conditions ruled out | Used when patient is observed for possible substance exposure and specimen authentication is needed |
Z13.89 | Encounter for screening for other disorder | Applicable when drug screening is ordered for surveillance or screening purposes (e.g., workplace) |
Z71.41 | Alcohol abuse counseling and surveillance of alcoholic | Relevant when monitoring for alcohol/substance use during treatment or counseling programs |
F11.20 | Opioid dependence, uncomplicated | Used when monitoring for relapse or adherence to treatment in opioid use disorder management |
R78.89 | Other specified abnormal findings of blood chemistry | Captures abnormal toxicology or unexpected laboratory findings prompting confirmatory testing and source authentication |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0007U | Proprietary PLA code: ToxProtect — presumptive urine drug screen with confirmation of identified drugs plus buccal swab DNA authentication of urine source | Primary billing code that describes the combined laboratory service provided by Genotox Laboratories LTD |
80305 | Drug screen, presumptive, any number of drug classes; any technique, capable of being read out visually (e.g., colorimetric), each patient encounter | May be used in facility or point-of-care settings for initial screening prior to sending specimens to reference lab when billed separately |
80307 | Drug screen, presumptive, any number of drug classes by instrumented analyzer, each patient encounter | Represents instrumented immunoassay screening methods that could precede confirmatory testing in workflow |
80320 | Confirmation test for drugs (e.g., GC-MS, LC-MS/MS), each separate drug class analyzed | Represents confirmatory testing methods used when the urine screen identifies substances requiring definitive confirmation |
81265 | DNA, short tandem repeat (STR) analysis, for human identification (example CPT for illustrative purpose) | Represents the type of DNA-based human identification testing used to authenticate specimen source; billing may vary and specific PLA covers this within 0007U |